Laboratory of America Holdings (Laboratory of America Holdings) Earnings per Share (Diluted) : $4.65 (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Laboratory of America Holdings Earnings per Share (Diluted)?

Laboratory of America Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-1.97. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $4.65.

Laboratory of America Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $-1.97. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $4.69.

Laboratory of America Holdings's EPS without NRI for the three months ended in Dec. 2023 was $3.30. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $12.56.

During the past 12 months, Laboratory of America Holdings's average EPS without NRIGrowth Rate was -0.80% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -11.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 12.80% per year.

During the past 13 years, Laboratory of America Holdings's highest 3-Year average EPS without NRI Growth Rate was 79.30% per year. The lowest was -53.40% per year. And the median was 15.30% per year.

Laboratory of America Holdings Earnings per Share (Diluted) Historical Data

The historical data trend for Laboratory of America Holdings's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratory of America Holdings Earnings per Share (Diluted) Chart

Laboratory of America Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

8.35

15.88

24.39

13.97

4.77

Laboratory of America Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															0.86	2.39	2.12	2.11	-1.97

Competitive Comparison of Laboratory of America Holdings's Earnings per Share (Diluted)

For the Diagnostics & Research subindustry, Laboratory of America Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratory of America Holdings's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Laboratory of America Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Laboratory of America Holdings's PE Ratio falls into.

Laboratory of America Holdings Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Laboratory of America Holdings's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(418	-	0)	/	87.600
	=	4.77

Laboratory of America Holdings's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-167.1	-	0)	/	85.500
	=	-1.95

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.65

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Laboratory of America Holdings (NYSE:LH) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Laboratory of America Holdings Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Laboratory of America Holdings's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratory of America Holdings (Laboratory of America Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Laboratory Corp of America Holdings (NYSE:LH) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

LH:Mexico L1CA34:Brazil

Address

358 South Main Street, Burlington, NC, USA, 27215

Website

https://www.labcorp.com

Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Executives

Peter J Wilkinson	officer: SVP, Chief Accounting Officer	C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Kerrii B Anderson	director	WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D	officer: SVP, Global General Counsel	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman	director	6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber	officer: CEO, Covance Drug Development	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder	officer: EVP, President-Diagnostics Lab	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey	officer: EVP, Chief Strategy Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo	officer: EVP, Pres, Central Labs & Intl	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham	officer: EVP, CHRO	C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike	officer: Pres & CEO Clinical Business	C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Kirsten Marie Kliphouse	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg	officer: Chief Financial Officer, EVP	P O BOX 1017, CHARLOTTE NC 28201-1017
Brian J Caveney	officer: SVP, Chief Medical Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215
R Sanders Williams	director	DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Amy B. Summy	officer: EVP, Chief Marketing Officer	531 SOUTH SPRING STREET, BURLINGTON NC 27215